Maternal exposure to Parvovirus B19 is managed by testing for what?

• A. Maternal IgG antibodies
• B. Maternal RNA levels
• C. Fetal ultrasound only
• D. Vaccination

Answer: (A)

Assessing maternal immunity to Parvovirus B19 relies on serology, specifically testing for IgG antibodies. A positive IgG indicates prior infection and protective immunity, meaning the fetus is at lower risk from exposure. If IgG is negative, the mother may be susceptible, and IgM testing may be used to detect an acute infection, which would prompt closer fetal monitoring. There is no vaccine for Parvovirus B19, and RNA levels aren’t used to determine exposure risk, while fetal ultrasound serves as surveillance rather than the initial exposure assessment.